This website is for UK Healthcare Professionals only

Expert Opinion

 

Dr William Tillet – Unmet Needs in PsA

Clinical Summary Videos

 

RINVOQ Discovery Journey & MOA 

SELECT PsA 2

SELECT-PsA 1

Clinical Summaries

SELECT-PSA 1

Trial of RINVOQ and Adalimumab for psoriatic
arthritis

SELECT-PSA 2

RINVOQ for psoriatic arthritis refractory to biologics: SELECT-PsA 2

UK-UPAD-220203. Date of preparation: August 2022

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com